A Comparative Study of Office-Based Injectable Buprenorphine in Opioid-Dependence

Abstract

Introduction

Opioid use disorder is a global epidemic and has recently become one of the most prevalent addictions in the United Arabe Erarits (UAE). Opioids have long-lasting harmful effects on human health as well as affect the quality of life in terms of psycho and social aspects. The high mortality in opioid dependence remains a significant problem. To date, the recovery rate for patients who suffer from Opiod Used Disorder OUD doesn't exceed 22% globally by receiving effective treatments available. This study aims to determine if injectable buprenorphine reduction of opioids, increases recovery rates, and improves the quality of life in opioid dependence by comparing the efficacy of buvidal treatment vs psychosocial treatment after opioid intoxication one-month period.

Methods

This is a longitudinal comparative study following 42 male inpatients and outpatients aged between18-65 years under the care of Erada canter for treatment and rehab – Dubai, who were admitted for detoxification and rehabilitation, between April 2020 to December 2021, and divided into two groups: 21 male patients who are receiving Buvidal Prolonged-Release Solution for Injection and completed at least 12 weeks of weekly Buvidal injection in a group; and Another group of 21 male patients who received psychosocial treatment for 12 weeks. Data collection from a medical record system, Urine Drug Test, Quantitative Data, Assessments as well as Semi-structured interviews, and a Generic quality of life questionnaire (QoL-5) were used to assess the quality of life domains.

Results

Buvidal Prolonged-Release Solution for Injection formations is a promising therapeutic option in OUD; it was found to play the most significant role in reducing opioid consumption and improving the recovery rate, it encourages users to engage more in the psychosocial treatment process and positively impacts their lives

Conclusions

This study definitively showed that Buvidal increased recovery rates among users of opioid substances and reduced opioid consumption as well as improved the quality of life among patients with Opioid Use Disorder. These studies provided evidence of therapeutic benefits in the field of opioid use disorder. Further studies are needed to establish and develop preventive and treatment measures.